Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses

• Published in: Journal of general virology Vol. 105; no. 5
• Main Authors: Giessler, K S, Goehring, L S, Jacob, S I, Davis, Allison, Esser, M M, Lee, Y, Zarski, L M, Weber, P S D, Hussey, G S
• Format: Journal Article
• Language: English
• Published: England 01.05.2024
• Subjects: Animals; Antibodies, Viral - blood; Cytokines - blood; Cytokines - immunology; Female; Herpesviridae Infections - immunology; Herpesviridae Infections - veterinary; Herpesviridae Infections - virology; Herpesvirus 1, Equid - immunology; Horse Diseases - immunology; Horse Diseases - virology; Horses; Immunoglobulin G - blood; Viremia - immunology; Viremia - veterinary; Virus Shedding; IgG subisotype; host immune response; herpesvirus pathogenesis; equine herpesvirus 1 (EHV-1); interferon; equine herpesvirus myeloencephalopathy (EHM)
• ISSN: 1465-2099
• DOI: 10.1099/jgv.0.001987

Herpesviruses establish a well-adapted balance with their host's immune system. Despite this co-evolutionary balance, infections can lead to severe disease including neurological disorders in their natural host. In horses, equine herpesvirus 1 (EHV-1) causes respiratory disease, abortions, neonatal foal death and myeloencephalopathy (EHM) in ~10 % of acute infections worldwide. Many aspects of EHM pathogenesis and protection from EHM are still poorly understood. However, it has been shown that the incidence of EHM increases to >70 % in female horses >20 years of age. In this study we used old mares as an experimental equine EHV-1 model of EHM to identify host-specific factors contributing to EHM. Following experimental infection with the neuropathogenic strain EHV-1 Ab4, old mares and yearling horses were studied for 21 days post-infection. Nasal viral shedding and cell-associated viremia were assessed by quantitative PCR. Cytokine/chemokine responses were evaluated in nasal secretions and cerebrospinal fluid (CSF) by Luminex assay and in whole blood by quantitative real-time PCR. EHV-1-specific IgG sub-isotype responses were measured by ELISA. All young horses developed respiratory disease and a bi-phasic fever post-infection, but only 1/9 horses exhibited ataxia. In contrast, respiratory disease was absent in old mares, but all old mares developed EHM that resulted in euthanasia in 6/9 old mares. Old mares also presented significantly decreased nasal viral shedding but higher viremia coinciding with a single fever peak at the onset of viremia. According to clinical disease manifestation, horses were sorted into an EHM group (nine old horses and one young horse) and a non-EHM group (eight young horses) for assessment of host immune responses. Non-EHM horses showed an early upregulation of IFN-α (nasal secretions), IRF7/IRF9, IL-1β, CXCL10 and TBET (blood) in addition to an IFN-γ upregulation during viremia (blood). In contrast, IFN-α levels in nasal secretions of EHM horses were low and peak levels of IRF7, IRF9, CXCL10 and TGF-β (blood) coincided with viremia. Moreover, EHM horses showed significantly higher IL-10 levels in nasal secretions, peripheral blood mononuclear cells and CSF and higher serum IgG3/5 antibody titres compared to non-EHM horses. These results suggest that protection from EHM depends on timely induction of type 1 IFN and upregulation cytokines and chemokines that are representative of cellular immunity. In contrast, induction of regulatory or TH-2 type immunity appeared to correlate with an increased risk for EHM. It is likely that future vaccine development for protection from EHM must target shifting this 'at-risk' immunophenotype.